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Summary
Resistance to antibiotics has recently increased dramatically
worldwide. The pipeline of new classes of antibiotics is dry
for at least the next few years. Therefore antibiotic resist-
ance represents one of the most problematic public health
issues of our time. Treatment failures already happen in in-
creasing numbers for common community-acquired infec-
tions, such as urinary tract infections or intra-abdominal
infections. This is due in particular to Enterobacteriaceae
harboring extended-spectrum beta-lactamases (ESBL).
Enterobacteriaceae harboring carbapenemases are also
highly prevalent in many countries. In the future, diffi-
cult surgical procedures, transplants, and other immuno-
suppressive therapies may become very risky. Resistance is
mainly due to an excessive usage of antibiotics, in both
humans and animals, and to cross-transmission of resist-
ant bacteria. Action is urgently needed. Therefore, a
World Alliance Against Antibiotic Resistance (WAAAR)
was created in 2011. It includes healthcare professionals,
consumers, health managers, and politicians. We present
here the main measures proposed by the Alliance, as a re-
sult of a strong consensus between the different stake-
holders, including general practitioners and veterinarians.
Antibiotics are in great danger [1]. Antibiotic resist-
ance has increased dramatically in the last few years,
and very few new compounds have been marketed in
the recent years, and will be made available in the next
few years [2]. Therefore, antibiotic resistance represents
one of the most important public health issues of our time
[3]. Meticillin-resistant Staphylococcus aureus (MRSA) in-
fections, in particular due to community-acquired MRSA
[4], are extremely prevalent in many countries, including
some European ones (European Center for Diseases
Control and Prevention. EARSS-Net database. http://ecdc.
europa.eu) [5], the USA, South America and Asia. Preva-
lence of MRSA infections decreased in the last few years in
many European countries, and this can be considered as a
very positive and promising result. Vancomycin-resistant
enterococci (VRE) are also very frequent, with large differ-
ences between countries. In the European point preva-
lence study organized by ECDC [6], VRE prevalence was
going from 1% to more than 50%. The prevalence of
Escherichia coli and Klebsiella pneumoniae harboring
extended-spectrum beta lactamases (ESBL) is increasing
regularly worldwide [7] reaching 50 to 70% for Escherichia
coli in some European or Asian countries [5,7]. In the
European point prevalence study, prevalence of Klebsiella
pneumoniae with carbapenemases was going from 1% to
more than 50% [6]. Because they are worried by possible
failures for their patients due to those resistant bacteria,
clinicians overuse carbapenems, our last line of therapy, to
treat common community infections like urinary tract in-
fections or intra-abdominal infections. As a consequence,
carbapenemases are more and more frequent in Entero-
bacteriaceae, Pseudomonas aeruginosa and Acinetobacter
spp. The prevalence of those multi-resistant strains is very
high in several countries like Greece, Turkey, Italy, North
African countries and Asian countries, in particular India
[8]. People who come back from those countries can carry
those resistant strains in their digestive tract and can
transmit those strains to other patients in the hospital
or to their relatives in the community [9]. If the car-
riage is not detected early enough in the hospitals, this
can lead to outbreaks. Extensively resistant, or even
pan-resistant strains are more and more common, in
particular in the ICU [10,11]. Old drugs like colistin
have to be used more and more frequently, and strains
resistant to colistin have been regularly described over
the past few years [12]. Morbidity and mortality due to
antibiotic resistance are substantial. It is estimated that
25.000 patients in Europe, and 23.000 patients in the
USA die every year from infections due to multi-
resistant bacteria. The cost induced by antibiotic resist-
ance is 1.5 Billion Euros (European Centre for Infection
Control and Prevention and European Medicines Agency
release 2009). In the future, difficult surgical procedures,
transplants, and other immunosuppressive therapies may
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become very risky. Resistance is due to many factors, in
particular the overuse of antibiotics in both humans and
animals, and the cross-transmission of resistant micro-
organisms in both the community, the hospitals and the
livestocks.
Antibiotics are very special drugs because their target
is a living one, able to adapt and become resistant to the
drug. This is very unique. In addition, the effect of anti-
biotics is not only visible in the treated patients, but also
in other patients, since antibiotics act not only on the
micro-organism(s) responsible for the treated infection,
but also on the commensal flora. The gut is the silent
epicentre of antibiotic resistance, because the antibiotics
modify profoundly the gut microbiome, and allow resist-
ant micro-organisms to grow and to colonize this organ
for prolonged periods of time [9]. Those resistant strains
can then be transferred to other patients in the hospitals,
or to relatives in the community. Antibiotics, and resist-
ant micro-organisms present in the effluents can con-
taminate the environment [13]. Micro-organisms carried
by animals can contaminate humans via either the envir-
onment or the food chain [14].
Antibiotics are overused nearly everywhere. There are
huge differences in their usage between countries. For
example, Scandinavian countries use one third of the
amount used by countries like France and Greece [15].
There is a clear relationship between the consumption
of antibiotics and the resistance level [16]. It is more
than unlikely that Scandinavian patients are less well
treated than patients in France or Greece. In fact, life ex-
pectancy is even longer in Scandinavia than in many
other countries. It is known that in certain countries be-
tween one third and half of the antibiotic therapies are
either unnecessary or inappropriate, both in the in- and
the outpatient settings. Patients are very often treated
with antibiotics for viral diseases, in particular for upper
tract respiratory infections, or for simple colonization, in
particular for asymptomatic bacteriuria. Even when the
treatment is indicated, patients are often treated for too
long periods of time.
It is really time to act vigorously in order to save anti-
biotics through an active protection of available antibi-
otics and the acceleration of the innovation to bring new
drugs to the clinicians in the near future [17,18]. The ac-
tion must be global and worldwide.
WAAAR (World Alliance Against Antibiotic Resist-
ance) is a cross-cutting action plan designed by a group
of professionals and by the consumers’ group LIEN to
deal with the current emergency. This plan involves
healthcare providers (both in the in- and outpatient set-
tings), veterinary medicine professionals, politicians and
consumers. The problem of antibiotic resistance is of
immediate significance for current and future users of
the healthcare system, as well as for all of us in the
general population. WAAAR’s main objective is to raise
awareness regarding this public health concern, among
politicians, public health authorities, international agen-
cies, health care professionals, patients, and the entire
population, who represent the target of our action.
The World Alliance Against Antibiotic Resistance is a
group of about 700 individuals representing all the key
stakeholders including healthcare system users: “Infec-
tions nosocomiales, sécurité des soins, accompagnement
des maladies” (LIEN), Collectif inter-associatif pour la
santé (CISS), Patients for Patient Safety [WHO], and the
Association for the Defense of Victims of Nosocomial
Infections [ADVIN] in Quebec). People are coming from
55 different countries. The Alliance receives support
from 85 learned societies and 55 various professional
groups in France and throughout the world. It is a non-
profit organization (French law of 1901) open to profes-
sionals and users worldwide. The alliance is not sponsored
by the pharmaceutical industry.
We present here the main measures advocated by
WAAAR to curb antibiotic resistance:
Antibiotics must be actively protected like as a pre-
cious resource [17]. Antibiotic prescription is still con-
sidered everywhere like a trivial act. In many countries
antibiotics are available “over the counter”. This must be
combated, as well as the use of counterfeit or outdated
antibiotics. Antibiotics are widely available and wasted
in developed countries, but the access to those drugs is
limited in many developing ones [19]. Like for water and
food, this is not acceptable.
Antibiotic stewardship programs must be implemented
everywhere [20]. Again, antibiotics being very special
drugs, special ways to prescribe antibiotics must be imple-
mented. They must be prescribed on dedicated nomina-
tive forms. For some antibiotics, carefully listed in every
hospital, a prior authorization from an infectious diseases
(ID) specialist must be organized. This must be the case
for example for carbapenems, penicillins associated
with beta-lactamases inhibitors, colistin, tigecyclin, gly-
copeptides, daptomycin, or oxazolidinones. A system-
atic re-evaluation must be scheduled around day 3 of
therapy [21]. At this stage, a de-escalation is frequently
possible. It is more difficult to implement this re-
evaluation in primary care, but the concept is still valid
for most infections. Duration of therapy must be care-
fully determined, be as short as possible and mentioned
on the very initial prescription. PK/PD considerations
are also very important issues. It is very frequent to use
too low dosages of antibiotics, in particular in obese pa-
tients, or in severely ill patients in the intensive care
units (ICU). In some cases antibiotic blood levels must
be monitored. Finally, both in the community and the
hospitals,in humans and animals, the use of cephalo-
sporins and fluoroquinolones must be limited.
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Infection control measures are essential. The prevention
of cross-transmission of multi-resistant bacteria both in
hospitals, the community, and livestock is of paramount
importance. Hand hygiene is the most important action.
Isolation procedures are also important, as well as the
whole body disinfection with chlorhexidine in patients in
the ICU [22].
Environmental measures are also of paramount im-
portance. Sanitation problems are very problematic in
many countries. Everything must be done to treat used
water, in particular when coming from the hospitals or
the farming facilities.
Antibiotics or treatment strategies for veterinary medi-
cine that have the smallest possible ecological impact
must be promoted. A ban on the use of antibiotics as
growth factors, a ban on their prophylactic use, the limita-
tion of the use of antibiotics critical for humans, like ceph-
alosporins and fluoroquinolones are important points.
The development of new antibiotics needs the imple-
mentation of innovative measures (cooperation between
companies, private/public cooperation, increase in the
duration of the patent of the drugs, financial reward, or-
phan drugs-like programs….). A user fee in veterinary
medicine has been recently advocated [23].
The expansion of basic and applied research efforts in
human and veterinary medicine is key. Large budgets
have been allocated in the past few years, particularly by
the NIH or the European commission, but more re-
sources are needed.
Available vaccines (pneumococcus, influenza virus…)
must be widely used. New vaccines must be developed.
Alternatives to antibiotics are also a promising strategy
(drugs acting upon virulence and upon quorum sensing
for example).
A widespread use of rapid diagnostic tests, with the
goal of limiting the prescription of antibiotics to proven
bacterial infections only, is needed. New tests need to be
developed, and the use of existing tests should be pro-
moted. As an example, in France, rapid antigen diagnos-
tic tests for acute pharyngitis are underused by general
practitioners, although they are freely available [24].
A surveillance of antibiotic resistance and use, with
regular feedback to healthcare professionals and the
public is necessary. There are efficient networks in cer-
tain countries and continents [5,15], but they are lacking
in most countries.
Education and training programs for healthcare pro-
fessionals and consumers are of considerable importance
[25]. Large information campaigns have been shown to
be very efficient [26].
Safeguarding antibiotics requires an orchestrated effort
carried out jointly by healthcare system users and pre-
scribers (in the broad sense of the term) [27,28]. There-
fore, WAAAR has chosen as its primary objective to
raise awareness among all stakeholders of the urgency and
magnitude of the threat. The Alliance must lobby actively
for antibiotics beyond the circle of insiders in order to
raise awareness among policy-makers, international health
organizations (World Health Organization (WHO), World
Organization for Animal Health (OIE), Food and Agricul-
ture Organization of the united Nations (FAO), European
Centre for Disease Prevention and Control….), and
the entire population. WAAAR works with other non-
governmental organizations like the Alliance for the
Prudent Use of Antibiotics (APUA), the Global Antibiotic
Resistance Partnership (GARP),the Action on Antibiotic
Resistance (REACT) and Antibiotic Action. WAAAR in-
tends to ask the UNESCO to put the “concept of antibi-
otics” on the list of the immaterial world heritage.
 The Alliance intends to launch a solemn declaration
against antibiotic resistance. This document will be
widely promoted, and published in many different
journals worldwide.
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